Kingswood Wealth Advisors LLC Raises Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Kingswood Wealth Advisors LLC raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 52.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 3,840 shares of the medical equipment provider’s stock after acquiring an additional 1,327 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Intuitive Surgical were worth $1,708,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Baystate Wealth Management LLC lifted its stake in shares of Intuitive Surgical by 150.0% in the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the period. Creekmur Asset Management LLC increased its holdings in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. MCF Advisors LLC increased its holdings in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 40 shares in the last quarter. Able Wealth Management LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter worth about $28,000. Finally, Delos Wealth Advisors LLC grew its position in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Trading Up 0.4 %

NASDAQ ISRG traded up $1.60 during trading hours on Wednesday, reaching $449.26. The company had a trading volume of 1,702,541 shares, compared to its average volume of 1,574,361. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $468.78. The stock has a market capitalization of $159.35 billion, a P/E ratio of 82.85, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39. The stock has a 50-day moving average of $433.72 and a 200 day moving average of $402.67.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the firm earned $1.18 EPS. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of recent analyst reports. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price target for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Barclays increased their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research report on Thursday, July 18th. Stifel Nicolaus upped their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research report on Friday, July 19th. Piper Sandler increased their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Finally, Jefferies Financial Group upped their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $442.30.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 239 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $385.55, for a total transaction of $92,146.45. Following the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,123,223.85. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 239 shares of the company’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $385.55, for a total transaction of $92,146.45. Following the sale, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,123,223.85. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. Insiders sold 16,005 shares of company stock worth $6,894,422 in the last three months. 0.90% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.